[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578924":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":44,"collaborators":11,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":11,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":11,"enrollmentInfo":56,"targetDuration":11,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":11,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Korea University Anam Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients diagnosed with Full-Thickness Rotator Cuff Tears, Including Massive and Large Tears","EXPERIMENTAL",null,[13],"Biological: Injection allogenic Umbilical Cord-derived Mesenchymal Stem Cell",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"BIOLOGICAL","Injection allogenic Umbilical Cord-derived Mesenchymal Stem Cell","Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell\n\n1. Injection dosage and volume of the study drugs:\n\n   * Low dose: 2.5X10 cells\u002F0.5mL\n2. Number of injections: Only once during the study period\n3. Device: Ultrasound\n4. Injection technique: Injection into the lesion by investigator\n\nBiological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell\n\n1. Injection dosage and volume of the study drugs:\n\n   \\- High dose: 5X10 cells\u002F1mL\n2. Number of injections: Only once during the study period\n3. Device: Ultrasound\n4. Injection technique: Injection into the lesion by investigator",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Woong Kyo Jeong","CONTACT","82-10-4047-2878","drshoulder@korea.ac.kr",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":11,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Korea University Anamh Hospital","RECRUITING","Seoul","Korea","02841","South Korea",{"type":35,"coordinates":36},"Point",[37,38],126.9784,37.566,{"lat":38,"lon":37},[41],{"name":11,"role":23,"phone":42,"phoneExt":11,"email":43},"+82-2-870-3246","eunmiahn@scorlab.kr",{"type":45,"investigatorFullName":22,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","PI","100578924","arthroscopic-rotator-cuff-repair-with-uc-mscs-for-large-to-massive-tears-100578924",false,"NCT06817616","Arthroscopic Rotator Cuff Repair with UC-MSCs for Large to Massive Tears","Arthroscopic Rotator Cuff Repair with Umbilical Cord-derived Mesenchymal Stem Cells for Large to Massive Rotator Cuff Tears","Inclusion Criteria:\n\n* Male or female 19 years of age and older\n* Unilateral shoulder pain with a pain score of 4 or higher.\n* patients with a symptom duration of at least three months who have not responded to conventional treatments, including analgesics.\n* patients diagnosed with massive or extensive full-thickness rotator cuff tears confirmed by computed tomography arthrography or magnetic resonance imaging.\n\nExclusion Criteria:\n\n* patients diagnosed with small or medium full-thickness rotator cuff tears among study participants with full-thickness rotator cuff tears.\n* patients who have received subacromial injection therapy in the affected shoulder within the past three months.\n* patients who have undergone rotator cuff surgery on the affected shoulder within the past six months.\n* patients exhibiting or suspected of having the following radiological findings: malignant tumors, severe glenohumeral osteoarthritis, or bony abnormalities causing subacromial space narrowing.\n* patients presenting with symptomatic cervical spine disorders.\n* patients experiencing bilateral shoulder pain.\n* patients diagnosed with multiple arthritis, infectious arthritis, rheumatoid arthritis, or fibromyalgia.\n* patients with neurological deficits.\n* Pregnant or breastfeeding patients\n* patients unwilling to use effective contraception during the study period.\n* patients currently infected with HBV, HCV, or HIV, or those with a positive RPR test result.\n* patients with severe conditions that may affect the study, including cardiovascular diseases, renal diseases, hepatic diseases, endocrine disorders, or malignancies.\n* patients who are unable to comprehend the questionnaires used for study assessments, including the Visual Analog Scale (VAS), or those with communication difficulties due to psychiatric disorders.\n* Any other cases deemed inappropriate for study participation by the investigator.","ALL","19 Years",{"count":57,"type":58},15,"ESTIMATED","INTERVENTIONAL",[61],"NA","Safety Analysis of Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells in Patients Undergoing Rotator Cuff Repair for Massive or Large Rotator Cuff Tears",[64],"Rotator Cuff Disease","2025-02-17",{"date":67,"type":68},"2025-02-18","ACTUAL",{"date":70,"type":68},"2025-01-17",{"date":72,"type":58},"2026-04",{"name":5,"class":6},1]